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Signal transduction networks are increasingly studied with mathematical modelling
approaches while each of them is suited for a particular problem. For the contextualisation
and analysis of signalling networks with steady-state protein data, we identified probabilistic
Boolean network (PBN) as a promising framework which could capture quantitative
changes of molecular changes at steady-state with a minimal parameterisation.
Results and Conclusion
In our case study, we successfully applied the PBN approach tomodel and analyse the dereg-
ulated Platelet-Derived Growth Factor (PDGF) signalling pathway in Gastrointestinal Stromal
Tumour (GIST). We experimentally determined a rich and accurate dataset of steady-state
profiles of selected downstream kinases of PDGF-receptor-alphamutants in combination with
inhibitor treatments. Applying the tool optPBN, we fitted a literature-derived candidate network
model to the training dataset consisting of single perturbation conditions. Model analysis sug-
gested several important crosstalk interactions. The validity of these predictions was further
investigated experimentally pointing to relevant ongoing crosstalk from PI3K to MAPK signal-
ling in tumour cells. The refined model was evaluated with a validation dataset comprising
multiple perturbation conditions. Themodel thereby showed excellent performance allowing
to quantitatively predict the combinatorial responses from the individual treatment results in
this cancer setting. The established optPBN pipeline is also widely applicable to gain a better
understanding of other signalling networks at steady-state in a context-specific fashion.
Introduction
Signal transduction networks are one of the core functional layers in cells. They convey intra- and
extra-cellular signals towards regulators which modulate the expression of cellular phenotypes
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corresponding to the types and concentrations of the stimuli [1]. In general, a signal transduction
network is a large and highly complex network comprising multiple intracellular signalling path-
ways such as mitogen-activated protein kinases (MAPK), phosphatidyl-inositide-3-kinases/AKT/
mammalian-target-of-Rapamycin (PI3K/AKT/mTOR), and phospholipase C gamma/protein
kinase C (PLCγ/PKC) pathways [2]. Also, there exist a number of crosstalk interactions between
these signalling pathways which help to fine-tune signals and to preserve the whole networks’
integrity upon perturbations [3–5]. In a physiological condition, signals from various stimuli are
integrated and transduced to regulate cellular functions and to maintain homeostasis of cellular
components [6]. Once the transfer processes of these signals are deregulated, the resulting aber-
rant signals often lead to abnormalities of cellular functions which were identified as the etiology
of many diseases including neurodegenerative diseases, metabolic diseases, as well as cancers
[7–9].
Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal
neoplasia of the gastrointestinal tract. These tumours commonly arise from gain of function
mutations of type III receptor tyrosine kinases, i.e. KIT in 78–90% of the cases and platelet-
derived growth factor alpha (PDGFRα) in 5–7% of the cases [10]. As constitutively active sur-
face receptors, these mutated proteins are the most upstream components of the cellular signal
transduction network. The first-line therapy for GISTs is surgical resection combined with
administration of Imatinib mesylate, a tyrosine kinase inhibitor with activities against ABL,
BCR-ABL, KIT, and PDGFRα/β. The clinical outcome of the first-line therapy is 35%-49% 9
years survival [11]. However, certain point mutations in GIST, e.g. an Aspartate (D) to Valine
(V) mutation at amino acid 842 on the PDGFRA gene, were also shown to be associated with
drug resistance [12]. Several hypotheses were proposed to explain the underlying molecular
mechanisms of oncogenic PDGFRα-driven GIST formation such as the retention of oncogenic
PDGFRα in intracellular compartments [13] or the deregulation of downstream oncogenic sig-
nalling pathways, see also [14]. Such hypotheses still require further investigation at the molec-
ular level to understand how signals are transduced and processed mechanistically in this
cancer setting.
In recent years, various modelling approaches in Systems Biology were applied to model
and analyse the properties of signal transduction networks in both physiological and pathologi-
cal conditions. This includes Bayesian networks [15], Boolean networks (BNs) [16], fuzzy logic
models [17], ordinary differential equation (ODE)-based models [18], partial differential equa-
tion (PDE)-based models [19] and also stochastic models [20], to list only a few examples.
Some modelling work also demonstrated the connections between the deregulation of signal
transduction networks to the pathophysiology of diseases, e.g. in metabolic disease [21] and in
cancers [22]. The choice of a suitable modelling framework is depended on the research ques-
tions and the associated applications.
In our study, we aim to assess the relevance of proposed crosstalk interactions from litera-
ture in the context of deregulated platelet derived growth factor (PDGF) signalling in gastroin-
testinal stromal tumour (GIST) based on steady-state protein data. On the experimental part,
we investigated a combination of different PDGFRαmutants and signalling molecule inhibi-
tors to dissect the molecular structure of the deregulated PDGF signalling pathway and to gen-
erate an extensive corresponding set of steady-state protein data. On the modelling part, we
applied probabilistic Boolean network (PBN) modelling, originally introduced by Shmulevich
et al. to model gene regulatory networks in the context of uncertainty [23], to assess the cross-
talk relevancy in PDGF signalling. With the assignment of probabilities on Boolean interac-
tions, a binarised-state PBN is capable to depict individual regulatory effects encoded as
Boolean rules in a stochastic manner and is thus suitable for determining the uncertain rele-
vance of crosstalk interactions. In addition, the molecular activities at steady-state can also be
A PBN Study on Deregulated PDGF Signalling in GIST
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represented by the steady-state distribution in the PBN framework, allowing them to be
directly compared to the normalised (non-discretized) steady-state protein data. For a recent
review see [24].
Apart from PBNs, there also exist many other modelling frameworks for the study of signal
transduction networks. However, each of them has some drawbacks when applied to this par-
ticular case study. Describing the connections between signalling molecules with conditional
probabilities in a Bayesian networks framework express their relationships quantitatively, but
such values do not capture the underlying regulatory mechanisms between molecules which
can be simplified and encoded as Boolean rules. Boolean networks can depict regulatory mech-
anisms of biochemical interactions with logic operators. However, the results do not capture
finer scale quantitative details of molecular kinetics. The variant many-valued logic networks
allow for a more fine-tuned description of molecular states but still suffer from the inherent
deterministic nature and does not allow to capture the uncertainty of network interactions.
Extensions of Boolean networks, e.g. by adding uncertainty in network states (e.g. by assigning
random initial conditions and/or random sequences of inputs) and accumulating the stochastic
results from multiple runs could also be applied to derive quantitative measures from the same
system [6,25]. However, one has to explicitly impose these additional considerations on top of
the conventional Boolean network framework while the probabilistic feature is already inte-
grated within the original PBN approach. More quantitative approaches such as fuzzy logic or
ODE-based models provide additional mechanistic details of the networks on a continuous
scale. However, they require an extensive amount of prior knowledge to define a suitable math-
ematical formula and require an extensive set of experimental data in order to infer kinetic
parameters.
With respect to PBN which belongs to the group of probabilistic logic models, other related
modelling frameworks in the same group such as Dynamic Bayesian networks (DBNs) and
Markov Login networks (MLNs) were also described. It was shown that the analytical results
from DBNs usually give similar results as PBN once the state transitional diagram is established
[26]. However, non-linear behaviour in biological network such as complex formation could
not be directly represented by conditional probabilities in dynamic Bayesian network while
such interaction can simply be encoded with logical operators in the PBN framework. In addi-
tion, it was shown that PBNs can also be represented in a more generalised form as Markov
Logic networks (MLNs) [27]. This approach is often applied in genetic studies where the net-
work structure is largely unknown and the connectivity between network components could be
highly dense [28]. Nevertheless, MLNs might not be suitable for the study of signal transduc-
tion networks in our case as the connections between molecules often occur in a one-to-one or
one-to-several manner and directional relationships between signalling molecules are mostly
well-documented. We therefore chose and applied PBN in our case study where we could show
that the PBN model is applicable for analysing the relevance of crosstalk interaction. In addi-
tion, we demonstrated that the PBN model could also predict combinatorial treatment results
from individual stimulation measurements with high accuracy.
Materials and Methods
Biological materials
The PDGFRα-mutant proteins were generated based on the pLNCX2-PDGFRα wild-type
expression plasmid generously provided by Prof. Andrius Kazlauskas (Boston). This sequence
was cloned to pcDNA5/FRT/TO-vector (Invitrogen™) and the constitutively active oncogenic
PDGFRαmutant occurring in GIST was generated by introducing the D842V point mutation
(PDGFRα-D842V-wild type, “DV-WT”). Based on the PDGFRα-D842V mutant, two
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PDGFRα-D842V-”knock-out”mutants were constructed by introducing tyrosine (Y) to phe-
nylalanine (F) point mutations, i.e. Y720F (PDGFRα-D842V-Y720F, “DV-dMAPK”) and
YY731/742FF (PDGFRα-D842V-YY731/742FF, “DV-dPI3K”) which have been shown to abro-
gate the recruitment of signalling molecules such as SHP2 and PI3K in the PDGFRα-wild type
receptor, respectively. All point mutations were introduced using the QuikChange kit (Strata-
gene) following the manufacturer’s recommendations.
For analysing the signalling behaviour of the mutant PDGFRα protein, an isogenic Flp-In™
cell line was constructed based on the Hek293 cell line which is naturally devoid of endogenous
expression of PDGFRα/β proteins. As such, Hek293 cells were co-transfected with the Flp-In™
target site vector (pFRT/lacZeo, Invitrogen™) and the regulatory vector (encoding Tetracycline
repressor protein, pcDNA™6/TR/invitrogen) using the TransIT1-LT1 transfection reagent
(Mirus) according to the manufacturer’s recommendations. Cell clones were selected by culti-
vation in presence of 10μg/ml Blasticidin and 100μg/ml Zeocin™ (both InvivoGen). Based on
this isogenic parental cell line (“293FR”), stable cell lines were generated by site directed recom-
bination by co-transfecting the transgene expression plasmid (pcDNA5/FRT/TO-based) in
combination with the Flp recombinase expression plasmid (pOG44, Invitogen). Stably trans-
fected cells were selected and cultivated in presence of 100μg/ml Hygromycin and 10μg/ml
Blasticidin [13].
Cell treatment andWestern blot analysis
Experiments were conducted by seeding 250,000 cells/well (12 well plate) in DMEM containing
10% FBS, 2% L-Glutamine, and 25mMHEPES on 12-well plates for 24–30 hours. Then,
growth media was exchanged and protein expression was induced by adding 5ng/ml doxycy-
cline (Sigma) under serum reduced (1% FBS) conditions for 14 hours and for additional 3
hours under serum free (0% FBS) conditions. Pharmacological inhibition was performed by
adding either 1μM of the PI3K inhibitor Wortmannin, 10μM of the MEK1,2 inhibitor U0126,
1μM of the pan-PKC inhibitor GF109203X, or 500nM for the PKC-α and PKC-β1 specific
inhibitor Gö6976. Wortmannin and Gö6976 were purchased from Sigma-aldrich while
GF109203X and U0126 were purchased from Calbiochem.
Cells were lysed on the dish with 300μl 1x Lämmli buffer. Cellular proteins were subjected
to SDS-PAGE, transferred to a nylon membrane (Amersham Hybond™-N/GE Healthcare by
ThermoFisher Scientific), blocked with 10% BSA and probed with the respective antibodies.
Alpha-tubulin was also probed as loading control. Phospho-specific antibodies against ERK1/2
(pThr202/pTyr204), PDGFRα (pTyr849)/β(pTyr857), AKT (pSer473) and PKC substrates
(pSer) were purchased from Cell Signaling. Phospho-specific antibodies for STAT5 (pTyr694)
and PLCγ1 (pTyr783) were purchased from BD Biosciences. Antibodies against PDGFRα (C-
20) were purchased from Santa Cruz Biotechnology1. Each gel was probed simultaneously
against alpha-tubulin to allow compensation for loading variations (using either antibody
DM1A/Santa Cruz Biotechnology1 or PA1-38814/Pierce™). The secondary antibodies were
coupled with IRdye, allowing imaging with the LI-COR Odyssey system. The relative intensi-
ties of Western blot images were quantified with Image Studio Lite version 4.0 using left-right
and top-bottom background subtraction. The experiments were done in 3 biological replicates
with 3 technical replicates on each Western blot. The calibrator sample was prepared from an
early passage of DV-WT cell line induced by 5ng/ml doxycycline.
Normalisation pipeline and datasets for modelling
Starting from the obtained raw experimental data, a quality control step was applied by dis-
carding 1) the data points overlapping with unspecific stains and 2) the data points with low
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signals due to blotting issues. Furthermore, data points with a corresponding tubulin signal of
less than 20 percent compared to the maximal signal within the same blot were removed from
the analysis due to low signal to noise ratio.
The remaining data points were first normalised to tubulin (loading control) and then to a
calibrator sample in order to correct for the differences across multiple blots. The normalised
mean of technical triplicates from each biological replicate were pooled and re-normalised to
the maximal value to generate the final mean and standard deviation for the modelling task.
We divided the initial set of experimental data into two parts. The training dataset com-
prises 6 experimental conditions including negative control (all signals assumed to be zero),
positive control (DV-WT) and 4 experimental conditions with single perturbations by YF
point mutations (DV-dMAPK and DV-dPI3K) or signalling inhibitors (DV-WT-Wortmannin
and DV-WT-U0126). The validation dataset comprises the 4 remaining experimental condi-
tions with combined perturbations.
Literature-derived PDGF signalling network
We built a mutant PDGF signalling network including the major downstream signalling pathways
including MAPK, PI3K/AKT/mTOR, PLCγ/PKC pathways, as well as STAT5 as another promi-
nent signalling target downstream of the oncogenic mutant (but not downstream of the wild-type
receptor) [13]. Interactions and regulatory mechanisms were modelled according to well-estab-
lished knowledge [29,30]. The recruitment sites of upstream signalling molecules to PDGFRα
were previously described [31,32]. Among the three major downstream signalling pathways in
PDGF signalling, there also exist a number of crosstalk interactions suggested by the literature as
listed in Table 1. In addition, apart from depicting the effects of inhibitors on their main targets,
we also included the information on an off-target effect of Wortmannin on conventional PKC
[33] which might be essential to explain the obtained signalling profiles in the context of GIST.
PBN description of PDGF signalling network
Based on the topology of the literature-derived PDGF signalling network, we built a corre-
sponding PBN model which comprises 27 nodes (molecules) and 40 edges (interactions). Mul-
tiple interactions directing onto one node were modelled as separated Boolean rules with the
corresponding selection probabilities. We applied the Boolean logic gate “OR” to combine
Table 1. References for the investigated crosstalk interactions in the PDGF signalling network.
Crosstalk number Descriptions References
1 Ras -> PI3K [34]
2 MEK1,2 -| Grb2SOS [35]
3 PI3K -> Ras [3]
4 PI3K -> MEK1,2 [5]
5 PIP3 -> GabSOS [36]
6 Akt -| GabSOS [37]
7 Akt -| Raf [4]
8 PLCγ -> PI3K [38]
9 PKC -> MEK1,2 [5]
The crosstalk interactions among MAPK, PI3K/AKT/mTOR and PLCγ/PKC pathways within PDGF
signalling as suggested by literature are listed. The annotation ‘->‘ refers to activation and the annotation ‘-|’
refers to inhibition.
doi:10.1371/journal.pone.0156223.t001
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non-exclusive inputs in the same class while inhibitions were represented by the combined
“AND” and “NOT” gates. Additionally, selection probabilities of the Boolean rules that repre-
sent the main pathways were assigned to be high with the flag “H”, while being fixed to low
with the flag “L” for all crosstalk interactions. This assignment ensures that the optimised selec-
tion probabilities for the interaction(s) with the flag “H” will always be higher compared to the
interaction(s) with the flag “L”. For instance, if there are two activating interactions directing
towards a single target node while one being from the main pathway and another being from
the crosstalk interaction, the bound of the optimised selection probability for the main interac-
tion (with flag “H”) will be from 0.5 to 1.0 while it will be from 0 to 0.5 for the crosstalk interac-
tion (with flag “L”). This implementation is integrated in the latest version of the optPBN
toolbox (version 2.2.3) available on http://sourceforge.net/projects/optpbn. The full set of
model descriptions and the implementation of the Boolean rules including the assignment of
“H” and “L” flags can be found in S1 File and the computational scripts of the PBN models, as
well as the example of results are included in S2 File.
Optimisation
We applied the grid-based version of the optPBN toolbox (version 2.2.3) to perform the optimi-
sation and analysis [39]. The model description of the PDGF signalling network in the PBN
format was combined with the steady-state measurement data of 6 signalling molecules includ-
ing the phosphorylated forms of PDGFRα, of PLCγ, of STAT5, of PKC substrates, of ERK1,2,
and of AKT, to generate an optimisation problem. The aim of the optimisation is to identify
the selection probabilities of each Boolean interaction in the PBN model that return steady-
state properties, i.e. the stationary distributions of the molecular states, which match the mea-
surement data. In the optPBN framework, we represent the dynamics of a PBN as an ergodic
Markov chain where we ensure ergodicity by introducing a small perturbation parameter ‘p’ to
randomly perturb the states [40]. The resulting ergodic Markov chain is therefore irreducible
(all states can be reached by any other states) and aperiodic (all states can be revisited in a non-
periodic manner) thus possessing a unique stationary distribution regardless to the initial con-
ditions. The two-state Markov chain approach was subsequently applied to determine the
number of necessary time steps to reach steady-state and to approximate the marginalised
steady-state distribution of each output state with a certain accuracy [41] (see also the pipeline
in Fig 1). All parameter values were chosen according to the previous study [39] i.e. the pertur-
bation parameter ‘p’ = 0.001, the range of accuracy parameter ‘r’ = 0.025, and the probability to
acquire results at the defined accuracy ‘s’ = 0.95, to ensure the creation of ergodic Markov
chains based on random perturbations while the steady-state distribution of each node was
minimally perturbed and the approximation of the steady-state distribution is relatively accu-
rate. In the last step, the sum of squared error (SSE) comparing the simulated molecular states
and the measurement data was calculated as indicator for the goodness-of-fit.
In the investigated PBN model of PDGF signalling, up to 27 selection probabilities were
optimised on the Grid’5000 infrastructure using 160 parallel cores (Intel CPU @2.50Ghz,
16GB ram). 5,000 samples of parameter sets were evaluated by two optimisation algorithms,
namely, differential evolution (DE) and evolutionary algorithm (EA). Three rounds of optimi-
sation were performed where we observed that the optimisation results generated by the DE
algorithm were converged already after 1,500 iterations (result not shown). The best fitting cost
from the DE algorithm was chosen for the comparison of the fitting quality between model var-
iants along with Akaike’s Information Criterion (AIC) [42,43] and the F-test for regression
model. The mean and distribution of the optimised selection probabilities based on the best
500 parameter sets were subsequently analysed.
A PBN Study on Deregulated PDGF Signalling in GIST
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Modelling of the deregulated PDGF signalling in BN and ODE-based
frameworks
We applied the BN/PBN toolbox [44] and the Systems Biology toolbox 2 (SBTB2) revision 72
[45] to model and analyse the deregulated PDGF signalling in GIST also in BN and ODE
frameworks, respectively. Regarding modelling in the BN framework, we removed all negative
feedbacks on the node PDGFR, removed the basal activities of PTEN and PDK, as well as
assumed that Wortmannin does not inhibit PKC efficiently, in order to obtain the best possible
fitting in the BN framework. For ODE modelling, we applied the law of mass action to convert
the interaction graph of deregulated PDGF signalling into a set of ordinary differential equa-
tions, see an example in [20]. We also added deactivation/degradation reactions and their cor-
responding parameters for each molecule to balance the activation/synthesis. 20 independent
optimisation runs of the ODE model were performed using 50,000 parameter sets applying the
particle swarm algorithm (global optimiser) followed by testing another 50,000 parameter sets
applying the Simplex algorithm (local optimiser) with a parameter range from 0 to 100. The
best fitting cost from the ODE model was compared to the ones from the BN and PBN
approaches while the distribution of optimised parameters from all 20 optimisation runs was
compared to the ones of the PBN model. The complete set of computational scripts and model-
ling results is available on http://sourceforge.net/projects/optpbn.
Results
Incomplete inhibition and potential influence of crosstalk interactions
were observed from experimental data
We investigated the signalling profiles of three PDGFRαmutants, i.e. DV-WT, DV-dMAPK
and DV-dPI3K in combinatorial treatment with two signalling inhibitors, i.e. Wortmannin
and U0126. According to the results from theWestern blot investigation (Fig 2), the cell system
and the signalling inhibitors functioned properly. We observed that PDGFRα transgenes were
expressed exclusively upon doxycycline induction and that basal phosphorylation of the signal-
ling molecules was very low. Also, phosphorylated PDGFRα (pPDGFRα) signals were found to
Fig 1. Approximation of the steady-state distribution in the optPBN framework. The dynamic behaviour of the PBNmodel was represented as a
Markov chain. A small perturbation parameter ‘p’was introduced to ensure the ergodicity of the respective Markov chain which is rendered irreducible (all
states can be reached by any other states) and aperiodic (all states can be revisited in a non-periodic manner) thus possessing a unique steady-state
distribution independent of the initial conditions. The two-state Markov chain approach was subsequently applied to determine the number of necessary time
steps to reach the steady-state (burn-in period) and to collect sufficiently large number of samples in order to approximate the marginalised steady-state
distribution of the output states for a defined (adjustable) accuracy. Note that multiple evaluations of the burn-in period and collected samples might be
needed. The approximated steady-state distribution corresponds to the probability of the output node(s) being ON, i.e. being 1, as determined from the
collected samples.
doi:10.1371/journal.pone.0156223.g001
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be comparable between the different mutants (Fig 2). This observation also applies to phos-
phorylated STAT5 (pSTAT5) signals. The phosphorylated PLCγ (pPLCγ) signals dropped in
the DV-dMAPKmutant, indicating that the SHP-2 recruiting motif Y720 also affects PLCγ
activation (see Fig 2). In parallel, decreased activities of downstream signalling molecules, i.e.
Fig 2. Raw and quantified data from the initial set of Western blot experiments. [A] An example set of raw data fromWestern blot experiments is
shown in Fig 2A. Three PDGFRαmutants containing the D842V point mutation were investigated. One mutant contains no additional YF point mutation,
i.e. wild type (DV-WT) while the other two contain either Y720F (DV-dMAPK) or YY731/742FF (DV-dPI3K) point mutations which abrogate the recruitment
sites of upstream signalling molecule for MAPK and PI3K/AKT/mTOR pathways, respectively. These experimental conditions were combined with the
treatment with two signalling inhibitors, i.e. Wortmannin (W) [1 μM], which mainly inhibits PI3K, and U0126 (U) [10 μM], which mainly inhibits MEK1,2.
Doxycycline is used to induce the transcription of the constitutively phosphorylated PDGFRαmutants. The experiment was performed in 3 biological
replicates with 3 technical replicates. The signals from the calibrator sample (C) derived from the induced DV-WT cell line in an early passage were
applied to calibrate relative intensities betweenWestern blots. [B] The summarised quantifiedWestern blot data are shown in Fig 2B. The signals were
normalised against tubulin and subsequently calibrated by the calibrator signals. The normalised mean of technical triplicates from each biological
replicate were pooled and re-normalised to the maximal value to generate the final mean and standard deviation values for modelling task. The
significances between two data points were assessed with the Student’s T-test; p-value < 0.05 (*) and p-value < 0.01 (**).
doi:10.1371/journal.pone.0156223.g002
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phosphorylated ERK1,2 (pERK1,2) and phosphorylated AKT (pAKT) were observed in accor-
dance to the inhibitory effects of YF mutants and the signalling inhibitors. These results indi-
cate that the abrogation of recruitment sites by point mutations and the signalling inhibitors
worked effectively on their primary targets. In addition, we found that neither the construc-
tions of our cell system nor the inhibitor treatments used in the study affect the expression
level of the investigated signalling components (see [13] and S1 Fig).
Among the inhibitory effects that we investigated, we observed that both Wortmannin and
U0126 reduced the phosphorylation of their downstream signalling targets almost completely.
In contrast, the DV mutants with additional YF point mutations delivered only partial inhibi-
tion, e.g. the signals of pERK1,2 and pPLCγ in DV-dMAPKmutants are only reduced by half.
In parallel, some evidences of crosstalk interaction were observed in the dataset. For instance,
inhibiting PI3K with Wortmannin also decreased the pERK1,2 signal in the MAPK pathway
while inhibiting MEK1,2 with U0126 additionally increased the pAKT signal in the PI3K/
AKT/mTOR pathway (Fig 2B). It should be noted that the cross-regulation through Wortman-
nin inhibition is stronger than the one via U0126, with up to 39% decreased pERK1,2 signal
versus up to 25% increased pAKT signal compared to the untreated conditions. Also, the
cross-regulation by Wortmannin is significant in 2 out of 3 mutants while the crossed inhibi-
tory effect mediated by U0126 was significant only in the DV-WT condition (Fig 2).
Initial data integration in the PBN framework suggested important
crosstalk interactions from candidate network
We integrated this initial dataset into the literature-derived PBN model of PDGF signalling by
applying the tool optPBN. The model structure and the splitting of datasets are shown in Fig 3.
Initially, we started with a model topology without any crosstalk interaction to explore if the
model that contains only the major oncogenic pathways would already be sufficient to fit the
training dataset. The results showed that the initial model fitted well to pPDGFR, pSTAT5 and
pAKT data, but still could not capture the decrease of pERK1/2 signals after Wortmannin
treatment. Also, we found that a model variant with all-or-none inhibition could not fit well to
either the pERK1/2 or the pPLCγ data (see S2 Fig).
Next, we investigated 9 model variants where the crosstalk interactions proposed in the lit-
erature (Table 1) were added one-at-a-time and optimisation was re-performed (Table 2).
Only the positive crosstalk interactions from PI3K to Ras (Number 3), from PI3K to
MEK1,2 (Number 4) and from PKC to MEK1,2 (Number 9) could further improve model fit-
ting and allowed to distinguish the signal intensities of the DV-WT and DV-WT-Wortmannin
conditions (results not shown). In addition, the lowest AIC values and highest F values of these
model variants also support that these are the most preferential models to be further
investigated.
Iterative experimental investigation and model refinement revealed that
PKC activity is independent of PDGFRα activation and the crosstalk
interactions from PI3K towards MAPK pathway being the most relevant
To investigate the validity of these modelling results, we set-up an additional experiment by
treating the DV-WT mutant with PKC inhibitors (Pan-PKC inhibitor ‘GF109231X’ or conven-
tional-PKC specific inhibitor ‘Gö6976’) thereby also probing for phosphorylated PKC (pPKC)
substrates to investigate if the PKC inhibitors worked effectively (Fig 4).
While the PKC inhibitors exhibited a strong effect on their downstream primary target, the
results showed that PKC activity is independent of PDGFRα activation. Considering the posi-
tive crosstalk interaction from PKC towards MEK1,2, we initially expected to observe
A PBN Study on Deregulated PDGF Signalling in GIST
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decreased activities of pERK1,2 upon the reduction of pPKC substrate signals. However, we
witnessed to the contrary that the pERK1,2 signals increased after PKC-inhibitors treatments.
Regarding the fact that our initial model assumed pPKC signals to be dependent on pPDGFR
activation, we concluded that the crosstalk interaction from PKC towards MEK1,2 is not
important in our cellular context.
Fig 3. Model structure and datasets for modelling. [A] The model structure of the literature-derived PDGF signalling is shown in Fig 3A. The
constitutive activity of mutated PDGFRα (mPDGFR) is inducible by doxycycline (DOX). Downstream of mPDGFR includes 3 canonical intracellular
signalling pathways: MAPK, PI3K/AKT/mTOR and PLCγ/PKC pathways as well as regulatory mechanisms on PDGFRα. In addition, we included, STAT5,
which was shown to be rather activated by oncogenic PDGFRαmutants [13]. SHP2, PI3K and PLCγ, marked with asterisks, are the targets of YF
mutants. The basal activities of PTEN and PDK were represented by bPTEN and bPDK, respectively. Four signalling inhibitors, i.e. Wortmannin, U0126,
GF109231X (GF109), and Gö6976, and their targets are also depicted. The phosphorylation state of five downstream signalling molecules, i.e. PDGFRα,
STAT5, PLCγ, ERK1,2 and AKT were used as read-outs. There were 9 crosstalk interactions proposed in literature (numbered 1–9) that might be involved
in PDGF signalling. Note that the phosphorylation of PKC substrates (PKC) was also included as a read-out in the additional experiment (Fig 4) and the
read-out nodes with multiple inputs, i.e. PDGFRα, PLCγ, PKC and AKT are also optimised. [B] The quantifiedWestern blot data from 9 experimentally-
investigated conditions together with a negative control condition were applied for the modelling task. Experimental data were split into a training set
(single perturbation plus positive and negative controls) and a validation dataset (combinatorial perturbations).
doi:10.1371/journal.pone.0156223.g003
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On the counterpart, we still observed that pERK1,2 signals were decreased uponWortman-
nin treatment as previously shown in the initial set of experiments (Figs 2 and 4). This finding
supported the validity of the positive crosstalk interactions from PI3K towards MAPK path-
ways. In addition, we saw that pAKT and pERK1,2 signals are significantly up-regulated fol-
lowing PKC-inhibitor treatment. On the one hand, it could be an off-target effect of the two
PKC inhibitors on the negative regulators of both oncogenic pathways. On the other hand, the
off-target effect might only be applied to PI3K/AKT/mTOR pathway while the changes in
pERK1,2 signals were modulated by the positive crosstalk as suggested by the model.
Further model refinement by introducing basal PKC activity and by adding the 3 data points
from negative control, positive control and Wortmannin treatment conditions to the training
dataset confirmed in the one-at-a-time crosstalk adding experiment (Table 3, see also Table 2
for comparison) that the crosstalk interactions from PI3K to MAPK pathway are the only rele-
vant interactions that improve model fitting. We chose the refined model with the crosstalk
from PI3K to MEK1,2 which has the best fitting cost as the final model for further analysis.
Additional information on model complexity, the F-test and fitting costs from 3 optimisation
runs can be found in S3 File.
We found that the quality of plotted fitting results generated from the final model is very good
when compared to the training dataset (Fig 5) where similar results can be obtained from the
model variant with the crosstalk from PI3K to Ras (results not shown). We also explored all model
variants with pair-wise combinations of crosstalks and we found that only the model variants with
combined crosstalks including the ones from either PI3K to MEK1,2 or from PI3K to Ras have
better fitting costs. In addition, we observed that a model variant with both crosstalk interactions
from PI3K to the MAPK pathway integrated could not further improve the fitting cost (see S4
File), possibly due to redundancy. Either one of these two crosstalk interactions is sufficient to
explain the signalling profiles of the cancer-specific deregulated PDGF signalling in GIST.
The final PBN model of deregulated PDGF signalling in GIST is highly
predictive for combinatorial stimulations and provides quantitative
insights on signal flows
In order to evaluate the predictive power of the final PDGF model, we simulated the model
with combined perturbations conditions integrating YF point mutations (dMAPK and dPI3K)
Table 2. Fitting costs and AIC value of the initial model variants with and without crosstalk interactions.
Crosstalk number Descriptions Fitting cost AIC value
- No crosstalk 0.198 -104.62
1 Ras -> PI3K 0.193 -101.39
2 MEK1,2 -| Grb2SOS 0.197 -100.77
3 PI3K -> Ras 0.155 -107.97
4 PI3K -> MEK1,2 0.147 -109.56
5 PIP3 -> GabSOS 0.191 -101.70
6 Akt -| GabSOS 0.190 -101.86
7 Akt -| Raf 0.194 -101.23
8 PLCγ -> PI3K 0.197 -100.77
9 PKC -> MEK1,2 0.130 -113.24
The ﬁtting cost and AIC value of the initial PBN model without any crosstalk interaction was compared to the ones after adding crosstalk interactions one-
at-a-time. The ﬁtting cost is the sum of squared error between the simulated values and the mean values of measurement data in 6 experimental
conditions within the training dataset. The annotation ‘->‘ refers to activation and the annotation ‘-|’ refers to inhibition.
doi:10.1371/journal.pone.0156223.t002
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with signalling inhibitors (Wortmannin and U0126) and compared the model outputs to the
respective experimental data (validation dataset). The results are shown in Fig 6.
It was shown that our final PBN model predicts the molecular profiles of the combined
perturbations conditions in the validation dataset accurately. 18 out of 20 data points in com-
bined perturbation conditions were precisely predicted within the standard deviation of the
experimental data. The prediction of pERK1,2 in the DV-dPI3K-U0126 condition is close to
this error range. Also, the prediction on pSTAT5 in the same condition is qualitatively
Fig 4. Raw and quantified data from the additional set of Western blot experiments. [A] An example set of raw data from the additional Western blot
experiment to investigate the validity of modelling results are shown in Fig 4A. The PDGFRαmutant with D842V point mutation (DV-WT) was investigated.
Two additional signalling inhibitors, i.e. PKC-α and PKC-β1 specific inhibitor Gö6976 and pan-PKC inhibitor GF109203X together with the detection of
phosphorylated PKC (pPKC) substrates were included. Six experimental conditions were assigned, i.e. negative control without doxycycline induction
(ND), positive control with doxycycline induction but without inhibitor treatment (-), doxycycline induction with the treatment of Gö6976 (Gö) [500nM], of
GF109203X (GF) [1μM], of Wortmannin (W) [1μM] and of combined Gö6976 andWortmannin (Gö/W) [500nM/1μM]. The experiment was performed in 3
biological replicates with 3 technical replicates. [B] The summarised quantified data from the additional Western blot experiment are shown in Fig 4B.
Data were normalised against tubulin, then the mean values of technical triplicates from each biological replicates were pooled and re-normalised to
maximal values. The significances between two data points were assessed with the Student’s T-test; p-value < 0.05 (*) and p-value < 0.01 (**).
doi:10.1371/journal.pone.0156223.g004
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captured correctly. We suspect that this data point could be an experimental outlier due to its
distinctly low signal compared to the others on the same panel (see Fig 2). Overall, this analy-
sis demonstrates the excellent performance of the final PBN model in predicting combinato-
rial treatments.
Table 3. Fitting costs and AIC value of the refinedmodel variants with and without crosstalk interactions.
Crosstalk number Descriptions Fitting cost AIC value
- No crosstalk 0.208 -117.20
1 Ras -> PI3K 0.200 -114.50
2 MEK1,2 -| Grb2SOS 0.200 -114.50
3 PI3K -> Ras 0.163 -121.25
4 PI3K -> MEK1,2 0.162 -121.45
5 PIP3 -> GabSOS 0.200 -114.50
6 Akt -| GabSOS 0.197 -114.99
7 Akt -| Raf 0.202 -114.17
8 PLCγ -> PI3K 0.197 -114.99
9 PKC -> MEK1,2 0.201 -114.33
The ﬁtting cost and AIC value of the reﬁned PBN model variant without crosstalk interaction was compared to the ones after adding crosstalk interactions
one-at-a-time. The ﬁtting cost is the sum of square error between the simulated values and the mean values of measurement data in 6 experimental
conditions within the training dataset. The annotation ‘->‘ refers to activation and the annotation ‘-|’ refers to inhibition.
doi:10.1371/journal.pone.0156223.t003
Fig 5. Plotted fitting results of the final PBNmodel. Steady-state distributions of output states were generated from the final PBNmodel using the
optPBN toolbox. The mean and standard deviation (SD) of steady-state distribution from ten rounds of simulation (black stars [mean] and error bars [SD] on
top) were compared against the experimental data from the training dataset (multi-coloured squares [mean] and error bars [SD] on bottom). Six
experimental conditions as labelled on the x-axis are in the following order: DV-WT (WT[-]), DV-WT-Wortmannin (WT[W]), DV-WT-U0126 (WT[U]), DV-
dMAPK (dM[-]), DV-dPI3K (dP[-]), and negative control (no doxycycline induction, ND).
doi:10.1371/journal.pone.0156223.g005
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The model variant without any crosstalk interaction also returned a relatively good predic-
tion, except in the experimental conditions where the necessary crosstalk interaction takes
place (see S3 Fig). For instance, the discrepancy can be observed in the DV-dPI3K-Wortman-
nin condition where pERK1,2 signals were modulated by the crosstalk interaction from the
PI3K/AKT/mTOR pathway. In addition, we found that all single perturbation experiments are
needed in the training dataset in order to obtain a model with good predictive power for the
combined perturbation conditions. Removal of a single perturbation experiment from the
training dataset results in higher variabilities of output states (see S4 Fig).
Besides its predictive power, the final PBN model also summarises the quantitative signal
flow within the deregulated PDGF signalling network in GIST by considering the weights of
interactions represented by the optimised selection probabilities as shown in Fig 7.
Fig 6. Predictions from the final PBNmodel compared to the validation dataset. The mean and standard deviation of ten simulated values from the
final PBNmodel (black stars [means] and error bars [SD] on top) were compared against the experimental data from the validation dataset (multi-coloured
squares [mean] and error bars [SD] on bottom). Five molecules as labelled on the x-axis in four experimental conditions are in the following order: pSTAT5,
pPDGFRα, pPLCγ, pERK1,2 and pAKT.
doi:10.1371/journal.pone.0156223.g006
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The analysis demonstrates that among multiple crosstalk interactions that were proposed in
the literature to be involved in the PDGF signalling pathway, only one crosstalk is necessary to
explain the investigated experimental data in the context of GIST mutants in our cell system.
Also, it is shown that the weight of the crosstalk interaction from PI3K to MEK1,2 is not very
strong (0.226) compared to the main pathway (0.774). In parallel, it is shown that the weight of
basal PKC activity which is independent from the PDGFRα activation completely overrides the
activation signals from inositol 1,4,5-trisphosphate (IP3), diacylglycerol (DAG), and calcium
ion (Ca) (0.997 versus 0.003). The known inhibitory effects of the inhibitor are also reported
quantitatively, e.g. the effects of Wortmannin on its primary target PI3K (0.893) is stronger
than the one on its off-target molecule PKC (0.152) while U0126 has a strong inhibitory effect
on MEK1,2 (0.851) [5,46,47]. The complete list of the weights of the interactions from the final
PBN model can be found in S5 File.
Fig 7. Signal flow in the final PBNmodel. A quantitative overview of the signal flow in the final PBN is shown. The weights of interaction as represented
by the optimised selection probabilities in PBNmodel were classified into 5 categories: very low (< 0.1), low (0.1 to 0.3), medium (0.3 to 0.7), high (0.7 to
0.9), and very high (> 0.9) where the sizes of the arrows were adjusted accordingly. The crosstalk interactions that are not necessary in the context of GIST
were replaced with dotted grey arrows.
doi:10.1371/journal.pone.0156223.g007
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Discussion
Advantages of applying the PBN approach for analysing signal
transduction networks
In this research article, we demonstrated several advantages of applying the PBN approach for
analysing signal transduction networks with steady-state data. First, we experimentally showed
that the inhibitory effects of biological interventions do not work in an all-or-none fashion.
Such data call for modelling approaches that can capture quantitative changes of signalling
molecules where PBN approach serves the purpose well for capturing quantitative changes at
steady-state. Second, we showed that a PBN model with a compact model description and a
minimal parameterisation is sufficient to explain the signalling profiles observed at steady-
state. For a comparative purpose, an additional study on the comparison of the PBN results to
Boolean and ODE-based modelling can be found in S6 File. Third, we demonstrated that we
can study the importance of crosstalk interactions within the PBN framework by analysing the
fitting quality after adding an individual interaction. Also, the weights of interaction can be
derived quantitatively. Such results lead to the generation of new hypotheses on the importance
of crosstalk interactions that can subsequently be tested experimentally. Lastly, we showed that
we can predict the signalling profiles of combined perturbation experiments based on a PBN
model which was only trained on single perturbation experiments. This may be a promising
avenue for future studies to assess the effects of combinatorial perturbations or drugs treatment
by performing in silico prediction on PBN models prior to wet-lab experiments.
Unresolved issues and open questions from the study
There are several unresolved issues and open questions from the study. First, we observed in
our initial experimental that pAKT was up-regulated after U0126 treatment (significant in
DV-WT mutant). Some evidences were shown that MEK1,2 inhibition can lead to AKT up-
regulation but it was only demonstrated in breast and lung cancer models [48,49]. In addition,
this observation was not significant in the other two mutants in our initial set of experiment.
Second, Wortmannin was shown to potentially inhibit MEK1 (MKK1) [47] and this interac-
tion could replace the need of crosstalk interactions to fit our datasets (results not shown).
However, the study is based on in-vitro kinase assays so the threshold for the inhibitory effect
might differ substantially comparing to our cell-based experiments. Furthermore, other studies
failed to detect this potential inhibitory effect of Wortmannin on MEK1 [46] and [50]. Third,
we found that the model variant without any crosstalk interaction also has a relatively good
predictive power. One might argue that we do not need to investigate the importance of cross-
talk interactions nor to include them in the model. However, we still believe that crosstalk
interaction is an essential element that could not be left out from the models of signal transduc-
tion networks. To support our argument, we showed in Fig 6 that at least one essential crosstalk
interaction is required in the model to explain the observed signalling profiles. In addition,
recent literature supports the role of crosstalk interactions in providing a compensatory mech-
anism within signal transduction networks which was proven to be an important factor for the
discovery and design of therapeutic agents [51].
Technical issues, limitations, and outlook on PBNmodelling
There are some technical issues and limitations on the current implementation of PBN model-
ling that should be noted. For instance, the assignment of Boolean rules in our PBN model was
still performed manually. Hence, the rules might be inconsistent between different modellers.
Also, the assignment of importance on main pathways over crosstalk interactions might be
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biased, especially once dealing with less well-studied signalling pathways. On the technical
side, optPBN generated results based on an approximation of the steady-state distributions.
The approximation error might not be negligible for certain examples and the respective
parameters (precision and number of optimisation rounds) would have to be tuned accord-
ingly. In addition, even if the grid-based pipeline of optPBN can generate optimisation results
in an acceptable timeframe, large computational resources are needed to perform the calcula-
tion. This might consider to be a rate-limiting step in the workflow once there is a limited
amount of computational resources. This issue also posts a big challenge for analysing larger
signalling networks in the future.
To account for these issues and limitations, we foresee several potential improvements to be
implemented in the optPBN toolbox. First of all, we plan to build a standardised pipeline for
converting network interactions into PBN model structures. Such pipeline should eliminate
the variability of PBN modelling among different modellers. In terms of computation, a recent
PBN simulation tool on Java called “ASSA-PBN” was developed which allows for a more pre-
cise steady-state approximation and for faster calculations [52]. These features of ASSA-PBN
could be integrated into the optPBN framework in order to improve the efficiency and accuracy
of the results. On another perspective, PBN models might also be compiled into executable
scripts to gain a significant computational speed-up, similar to ODE model compilation pro-
vided by the Systems Biology toolbox 2 (SBTB2) [45].
As for an outlook into future applications, we envisage that the same analytical pipeline as
presented here could also be applied to study the properties of different signalling networks at
steady-state. Furthermore, since PBN is also widely used to model gene regulatory networks, it
is possible to build multi-scale models which connect the two functional layers within the PBN
framework in order to get more comprehensive insights.
Conclusion
We demonstrated a novel pipeline for modelling and analysing signal transduction networks
with steady-state data applying the PBN approach. By integrating normalised measurement
data at steady-state into an a priorimodel topology derived from literature using the tool
optPBN, we could generate a PBN model which fits well to signalling data at steady-state quan-
titatively. An additional experiment was performed to investigate the validity of predicted
crosstalk interactions. After a new round of experimental and modelling work, we generated a
final PBN model of the PDGF signalling network contextualized for GIST with a high predic-
tive power for predicting the combinatorial treatments from the individual stimulation mea-
surements. Such model could be further used to guide and reduce the number of experimental
conditions to be investigated in the lab. In addition, the analytical pipeline we presented could
also be used to study and analyse other signal transduction networks [53].
Supporting Information
S1 Fig. Expression level of signalling molecules in PDGFRαmutants. A panel of PDGFRα-
D842Vmutants with YF point mutations in a separated set of experiment is shown. The experi-
ments were performed following the same protocol as described in Materials andMethods. We
observed that different constructions of mutants, including the Y720F and YY731/742FFmutants
in our study, did not affect the expression level of the signalling molecules that we investigated.
(PDF)
S2 Fig. Compared fitting quality of the initial PBN variants with all-or-none inhibition ver-
sus with partial inhibition.Model simulations from two initial PBN model variants, one with
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all-or-none inhibition and another with partial inhibition, were compared against the training
dataset in 6 experimental conditions. The model variant with all-or-none inhibition could not
be fitted to the data points of pPLCγ and pERK1,2 in DV-dMAPK condition while the model
variant with partial inhibition fitted well to these data points. Nevertheless, the latter model
still could not distinguish the differences in pERK1,2 signals comparing between DV-WT and
DV-WT-Wortmannin conditions.
(PDF)
S3 Fig. Predictive power of the final PBNmodel versus the model variant without crosstalk.
Model simulations from the final model and the refined model variant without any crosstalk
interaction were compared against the validation dataset in 4 experimental conditions. Both
model variants have very good predictive power on most of the experimental conditions. Nev-
ertheless, the refined model variant without any crosstalk interaction could not accurately pre-
dict the change of pERK1,2 signal in DV-dPI3K-Wort condition which is modulated via
crosstalk signalling.
(PDF)
S4 Fig. Effect of single perturbation experiment removal on model prediction. The distribu-
tions of output state values from 20 optimisation runs of the final model and the model vari-
ants with a single perturbation experiment removed one-at-a-time were compared against the
validation dataset in 4 experimental conditions. The model variants with single perturbation
experiment removed have broader ranges of predicted output values (highlighted with red
boxes) where some do not agree well with the experimental data in the validation dataset.
(PDF)
S1 File. Model description of the PDGF signalling network in PBN format. This document
provides a detailed description of the PBN models of PDGF signalling presented in our study.
The model descriptions are divided into 3 sections: 1) The core model structure with major
intracellular signalling pathways, 2) The integration of crosstalk interactions proposed in litera-
ture, and 3) The final model structure after integrating data from the additional experiment.
Small examples within the computational scripts are also included in each section to illustrate
how each type of network interaction can be coded in the PBN format.
(PDF)
S2 File. Computational scripts of the PBN models and the result files from the modelling
studies. This compressed zip file comprises the following elements from modelling study: 1)
PBN model descriptions in the form of computational scripts, 2) Examples of result file from
grid-based computation, and 3) Saved model structures for grid computation. Instructions on
how to further analyse the result files and how to re-perform the optimisation are included.
(ZIP)
S3 File. Model complexities, F-test and fitting cost of model variants from 3 optimisation
runs. This spreadsheet provides the number of data points and the number of optimised
parameters for each model variant. In addition, the fitting costs from 3 optimisation runs of
each model variants are provided where only small variations between runs were observed.
The calculated AIC values and F values from F-test for regression model are also shown.
(XLSX)
S4 File. Fitting costs from pair-wise crosstalk combination study. This spreadsheet provides
the fitting costs of the model variants with pairs of combined crosstalk interactions comparing
to the ones with single crosstalk interaction (in diagonal) and without crosstalk interaction.
Only the model variants that include crosstalk number 3 (from PI3K to Ras) or number 4
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(from PI3K to MEK1,2) have better fitting cost.
(XLSX)
S5 File. Weights of interaction of the final PBNmodel. This spreadsheet provides a list of
Boolean interactions in the final PBN model together with the mean and standard deviation of
the optimised selection probabilities, i.e. weights of interaction, generated from the best 500
parameter sets of the optimisation. Very low overall standard deviations of the optimised
weights (mean = 0.03) indicate the high consistency of the optimisation result.
(XLS)
S6 File. Comparison of PBN versus Boolean network and ODE-based modelling results.
This document presents a comparison of PBN versus two other modelling frameworks which
are Boolean network and ODE-based modelling. This additional study includes model fitting
and predictions as well as a comparison of results from the three modelling approaches.
(PDF)
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